Risk for lung cancer higher for never smokers with COPD, ever smokers with or without COPD.
The incidence of osimertinib-associated grade 3 or higher cardiac adverse events was 4.9% in a retrospective NSCLC population.
Patients with cancer aged 65 and older are likely to be taking 5 or more medications before treatment with IV chemotherapy, which can complicate posttreatment care.
A phase 3 trial of elderly patients with nonsquamous NSCLC demonstrated that carboplatin + pemetrexed prolonged survival with an improved safety profile compared with docetaxel.
The approval was based on data from the CASPIAN study, an active-controlled, open-label trial that investigated the combination of durvalumab plus chemotherapy vs chemotherapy alone.